AEZS - Aeterna Zentaris shares rise 9% after initiating preclinical program in hypoparathyroidism

Aeterna Zentaris (AEZS) jumps 9% premarket on expansion of its pipeline by initiating a preclinical development program to develop parathyroid hormone fusion polypeptides ((PTH)) with delayed clearance based on intellectual property exclusively licensed by from The University of Sheffield, U.K. Primary hypoparathyroidism, the first indication to be pursued, is an orphan indication in the field of endocrinology. Aeterna will collaborate with Prof. Dr. Richard J. Ross and his laboratory at the University to continue to advance this potential new therapeutic being studied for chronic hypoparathyroidism in adults. Under the terms of the exclusive patent and know-how license agreement inked with the University, Aeterna obtained worldwide rights to develop, manufacture and commercialize PTH fusion polypeptides for an up-front cash payment of £100,000, certain milestone payments, as well as low single digit royalty payments on net sales of those products and certain fees payable in connection with sublicensing.Aeterna will be responsible for the further development and commercialization

For further details see:

Aeterna Zentaris shares rise 9% after initiating preclinical program in hypoparathyroidism